Genre
ReviewJournal
Date
2018-02-23Author
Boffo, SDamato, A
Alfano, L
Giordano, A
Subject
Acute myeloid leukemiaCDK9 inhibitor
Positive transcription elongation factor b
P-TEFb
MCL-1
MYC
Permanent link to this record
http://hdl.handle.net/20.500.12613/4788
Metadata
Show full item recordDOI
10.1186/s13046-018-0704-8Abstract
© 2018 The Author(s). Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.Citation to related work
Springer Science and Business Media LLCHas part
Journal of Experimental and Clinical Cancer ResearchADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/4770